Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The subject has a solid tumor. Expansion cohorts are limited to non-small cell lung cancer and/or pancreatic cancer with or without a KRAS mutation.
Tumor progression following at least one prior standard therapy, the subject refuses standard therapy, or no standard therapy exists.
The subject has a radiographically measurable tumor.
The subject is able to carry out daily life activities without difficulty.
The subject is able to swallow and retain oral medication.
The subject does not have significant side effects from previous anti-cancer treatment.
The subject has adequate organ and blood cell counts.
Sexually active subjects must use medically acceptable methods of contraception during the course of the study.
You may not be if
The subject has had major surgery or received certain types of cancer therapy within 2-3 weeks before starting the study.
The subject has a brain tumor.
Current severe, uncontrolled systemic disease.
History of clinically significant heart, lung, or eye/vision problems.
The subject has high blood pressure that is not well-controlled with medication.
The subject has a permanent pacemaker.
The subject is pregnant or breastfeeding.
Positive for Hepatitis B, Hepatitis C, or HIV.
Clareo Health | Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
